Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jagadish Boggavarapu

Allergy & Immunology Lakewood, CO Medical Doctor

NPI 1023177573 CMS profile 774

7700 W Virginia Ave, Unit B, Lakewood, CO 80226

Open in the dashboard

General payments

$2,675

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jagadish Boggavarapu of Lakewood, CO is reported in the CMS Open Payments database as having received $2,675 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $204 6
2024 General $418 27
2023 General $417 32
2022 General $437 56
2021 General $301 41
2020 General $206 19
2019 General $691 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jagadish Boggavarapu
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jagadish Boggavarapu were reported at $204. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jagadish Boggavarapu Allergy & Immunology median Middle half National median
2019 $691 $594 $163–$1,512 $163
2020 $206 $426 $106–$1,233 $114
2021 $301 $638 $157–$1,708 $132
2022 $437 $790 $205–$1,961 $149
2023 $417 $852 $220–$2,147 $160
2024 $418 $865 $203–$2,267 $164
2025 $204 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,292 164 payments
  2. AstraZeneca Pharmaceuticals LP $330 10 payments
  3. Regeneron Healthcare Solutions, Inc. $222 9 payments
  4. Sunovion Pharmaceuticals Inc. $221 23 payments
  5. Sanofi-Aventis U.S. LLC $170 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $108 6 payments
  7. Genentech USA, Inc. $88 6 payments
  8. Teva Pharmaceuticals USA, Inc. $73 5 payments
  9. Grifols USA, LLC $67 4 payments
  10. CSL Behring $47 3 payments
  11. Other $58 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,476 232 payments
  2. Education $199 5 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $700 93 payments
  2. TRELEGY ELLIPTA $290 41 payments
  3. NUCALA Respiratory $279 28 payments
  4. BREZTRI $259 5 payments
  5. FASENRA $247 4 payments
  6. DUPIXENT Inflammation And Immunology $222 9 payments
  7. LONHALA MAGNAIR $221 23 payments
  8. DUPIXENT Immunology $170 3 payments
  9. TEZSPIRE $139 1 payment
  10. Xolair $88 6 payments
  11. Other $471 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,122

Median for Allergy/ Immunology: 449

Drug cost

$562,106

Median for Allergy/ Immunology: $169,700

Branded share of claims

42.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucala Mepolizumab Brand 27 $100,791
Xolair Omalizumab Brand 23 $67,435
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 62 $62,343
Dupixent Pen Dupilumab Brand 15 $55,451
Advair Hfa Fluticasone Propion/Salmeterol Brand 95 $48,722
Spiriva Respimat Tiotropium Bromide Brand 60 $47,946
Breo Ellipta Fluticasone/Vilanterol Brand 81 $45,697
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 55 $36,152
Atrovent Hfa Ipratropium Bromide Brand 48 $25,155
Dulera Mometasone/Formoterol Brand 41 $14,034

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$162,171

Of which drugs: $116,096

Medicare patients

128

Average age 73

Services billed

8,996

84 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 55%
Diabetes 24%
Ischemic heart disease 23%
Osteoporosis 20%
Depression 18%
COPD 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 2,160 $209

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $127
$127 27 —
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $55
  • Regeneron Healthcare Solutions, Inc. $14
$69 15 —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $45
$45 — —
Xolair
  • Genentech USA, Inc. $44
$44 23 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $36
$36 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record